1. Home
  2. JBGS vs IOVA Comparison

JBGS vs IOVA Comparison

Compare JBGS & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JBG SMITH Properties

JBGS

JBG SMITH Properties

HOLD

Current Price

$16.56

Market Cap

1.0B

Sector

Real Estate

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$2.55

Market Cap

881.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JBGS
IOVA
Founded
2016
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
881.3M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
JBGS
IOVA
Price
$16.56
$2.55
Analyst Decision
Sell
Buy
Analyst Count
1
12
Target Price
$18.00
$10.45
AVG Volume (30 Days)
485.0K
12.5M
Earning Date
02-17-2026
02-26-2026
Dividend Yield
4.21%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$501,226,000.00
$250,425,000.00
Revenue This Year
N/A
$60.71
Revenue Next Year
$1.79
$59.35
P/E Ratio
N/A
N/A
Revenue Growth
N/A
175.62
52 Week Low
$13.28
$1.64
52 Week High
$24.30
$6.16

Technical Indicators

Market Signals
Indicator
JBGS
IOVA
Relative Strength Index (RSI) 42.94 47.81
Support Level $16.31 $2.25
Resistance Level $16.90 $2.77
Average True Range (ATR) 0.44 0.22
MACD -0.03 -0.03
Stochastic Oscillator 27.27 31.01

Price Performance

Historical Comparison
JBGS
IOVA

About JBGS JBG SMITH Properties

JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Share on Social Networks: